At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NVAX Novavax
Post-Mkt 10-20 16:19:51 EDT
11.43
+0.61
+5.64%
盘后11.43
+0.000.00%
16:18 EDT
High11.57Low10.55Vol6.50M
Open10.75D1 Closing10.82Amplitude9.43%
Mkt Cap1.88BTradable Cap1.63BTotal Shares164.43M
T/O72.80MT/O Rate4.55%Tradable Shares143.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

One Failed Endpoint Just Erased Most of EyePoint’s Value
Bellwether Stocks Movement  ·  10-20 13:23
One Failed Endpoint Just Erased Most of EyePoint’s Value
Novavax Inc. Stock Slides 4.0%, Underperforms Peers
Dow Jones  ·  10-20 04:34
Novavax Inc. Stock Slides 4.0%, Underperforms Peers
Moderna Stock Slumps, but It’s Too Early to Panic
Dow Jones  ·  10-19 11:00
Moderna Stock Slumps, but It’s Too Early to Panic
Novartis’ Pipeline Is Cracking—And The Stock Isn’t
Bellwether Stocks Movement  ·  10-17
Novartis’ Pipeline Is Cracking—And The Stock Isn’t
Himanshu H. Shah NOW Reports 6.46% Passive Stake in Novavax Inc as of Oct 16, 2026 - SEC Filing
THOMSON REUTERS  ·  10-17
Himanshu H. Shah NOW Reports 6.46% Passive Stake in Novavax Inc as of Oct 16, 2026 - SEC Filing
Himanshu Shah: Effective as of Oct 16, Shah Capital Filed to Voluntarily Withdraw Its Registration as an Investment Adviser with the U.S. SEC
THOMSON REUTERS  ·  10-17
Himanshu Shah: Effective as of Oct 16, Shah Capital Filed to Voluntarily Withdraw Its Registration as an Investment Adviser with the U.S. SEC
Himanshu Shah: Shah Capital no Longer Holds Novavax Shares with a Purpose of Influencing Control, Intend to Report on Schedule 13G Going Forward
THOMSON REUTERS  ·  10-17
Himanshu Shah: Shah Capital no Longer Holds Novavax Shares with a Purpose of Influencing Control, Intend to Report on Schedule 13G Going Forward
Movement Alert｜Novavax Falls 12.68% in Regular Trading, Shares Retreat After Sanofi Partnership Surge
Market Focus  ·  10-17
Movement Alert｜Novavax Falls 12.68% in Regular Trading, Shares Retreat After Sanofi Partnership Surge
Novavax falls -10.4%
TIPRANKS  ·  10-16
Novavax falls -10.4%
From Algorithms To Oncology: Why IAM Jumped On Day One
Bellwether Stocks Movement  ·  10-16
From Algorithms To Oncology: Why IAM Jumped On Day One
Inflation Shock Sends Wall Street Lower—Why Big Pharma Became The Market’s Refuge
Sector Pulse  ·  10-16
Inflation Shock Sends Wall Street Lower—Why Big Pharma Became The Market’s Refuge
Novavax Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  10-16
Novavax Inc. Stock Outperforms Competitors on Strong Trading Day
Pharma Stocks Jump. Eli Lilly, AstraZeneca up over 4%; Novo Nordisk up over 3%; Moderna, J&J, Merck, Pfizer up over 2%
Tiger Newspress  ·  10-15
Pharma Stocks Jump. Eli Lilly, AstraZeneca up over 4%; Novo Nordisk up over 3%; Moderna, J&J, Merck, Pfizer up over 2%
Novavax price target raised to $8 from $7 at Citi
TIPRANKS  ·  10-15
Novavax price target raised to $8 from $7 at Citi
Novavax Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  10-14
Novavax Inc. Stock Outperforms Competitors on Strong Trading Day
Novavax Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  10-10
Novavax Inc. Stock Outperforms Competitors on Strong Trading Day
Sector Update: Healthcare
MT Newswires Live  ·  10-10
Sector Update: Healthcare
Top Midday Stories: Delta Shares Fall After Q3 EPS, Revenue Misses; Apple Reportedly Cuts iPhone 18 Pro Component Orders Due to Soft Demand
MT Newswires Live  ·  10-10
Top Midday Stories: Delta Shares Fall After Q3 EPS, Revenue Misses; Apple Reportedly Cuts iPhone 18 Pro Component Orders Due to Soft Demand
Pharma Stocks Jump With Novavax up 12%, Moderna up 6%
Tiger Newspress  ·  10-09
Pharma Stocks Jump With Novavax up 12%, Moderna up 6%
BofA Adjusts Price Target on Novavax to $8 From $7, Keeps Underperform Rating
MT Newswires Live  ·  10-09
BofA Adjusts Price Target on Novavax to $8 From $7, Keeps Underperform Rating

Introduction

Company Name.
Novavax
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Issue price:
--